Reuters exclusively reports Lonza sets new goal to make Moderna COVID-19 vaccine ingredients

Reuters exclusively reported that Lonza aims to speed completion of two commercial production lines for Moderna Inc’s trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful. Moderna, which enlisted Lonza in May in a 10-year manufacturing contract, is racing with 100-plus other vaccine projects, having last week dosed initial participants in a 600-patient study.